Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Apr 4;4(4):355-358.
doi: 10.1016/j.jdcr.2017.11.005. eCollection 2018 May.

Propranolol as a potentially novel treatment of arteriovenous malformations

Jianyun Lu  1 , Radean Anvari  2 , Jinwei Wang  2   3 , Jian Huang  1 , Shiyao Pei  1 , Yaping Xiang  1 , Jinhua Huang  1 , Zhaoqi Yin  4 , Jing Chen  1 , J Stuart Nelson  2   5 , Wenbin Tan  2
Affiliations
Case Reports

Propranolol as a potentially novel treatment of arteriovenous malformations

Jianyun Lu et al. JAAD Case Rep. .
No abstract available

Keywords: AVM, arteriovenous malformation; MAPK; MAPK, mitogen-activated protein kinases; arteriovenous malformation; p-AKT, phosphorylated protein kinase B; p-ERK, phosphorylated extracellular signal-regulated kinases; p-JNK, phosphorylated c-Jun N-terminal protein kinases; p-PI3K, phosphorylated phosphatidylinositol 3-kinases; p-S6K, phosphorylated ribosomal s6 kinase; propranolol.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Patch and limb hypertrophy improved in the patient with an arteriovenous malformation treated with oral propranolol. The raised macular lesion as a protuberance before treatment (A), and lesion after 40 days of treatment (B). Regression of right lower limb hypertrophy after 40 days (C) and 5 months (D) of treatment.
Fig 2
Fig 2
A-H, Histologic examination the patient's AVM. A and B, H&E staining. C, Immunostaining with CD31, an endothelial cell marker. D-H, Activation of various mitogen-activated protein kinases in AVM blood vessels. Immunostaining with p-JNK (D), p-AKT (E), p-ERK (F), p-PI3K (G), and p-S6K (H). AVM, Arteriovenous malformation; H&E, hematoxylin-eosin staining; p-AKT, phosphorylated protein kinase B; p-ERK, phosphorylated extracellular signal-regulated kinases; p-JNK, phosphorylated c-Jun N-terminal protein kinases; p-PI3K, phosphorylated phosphatidylinositol 3-kinases; p-S6K, phosphorylated ribosomal s6 kinase.
See this image and copyright information in PMC

References

    1. International Society for the Study of Vascular Anomalies. Classification of vascular anomalies. Available at: http://www.issva.org/classification. Accessed April 2014.
    1. National Institute of Neurological Disorders and Stroke, National Institute of Health. Arteriovenous malformations. Available at: www.nlm.nih.gov/medlineplus/arteriovenousmalformations.html. Accessed July 2016.
    1. Lee B.B., Do Y.S., Yakes W., Kim D.I., Mattassi R., Hyon W.S. Management of arteriovenous malformations: a multidisciplinary approach. J Vasc Surg. 2004;39:590–600. - PubMed
    1. Anoop T.M., Sreejith P., Thomas J.K. Congenital subclavian arteriovenous malformation causing cardiac failure in an adult. J Am Soc Echocardiogr. 2009;22:864.e5–864.e6. - PubMed
    1. Pfohler C., Janssen E., Buecker A., Vogt T., Muller C.S. Successful treatment of a congenital extra-truncal vascular malformation by orally administered propranolol. J Dermatolog Treat. 2015;26:59–62. - PubMed

Publication types

LinkOut - more resources